Mergers & Acquisitions ·
Chemomab, Scipher amend merger agreement to set exchange ratio ensuring 10M post-closing shares
CMMBChemomab Therapeutics Ltd.
On September 23, 2026, Chemomab Therapeutics Ltd., Scipher Medicine Corporation, and related entities executed Amendment No. 1 to their Agreement and Plan of Merger. The amendment introduces a formula-based exchange ratio for the Domestication Merger to ensure the combined entity has exactly 10,000,000 shares outstanding immediately following closing. This technical adjustment does not alter the transaction's economic value or relative ownership allocation between Chemomab and Scipher. The merger is expected to close in the fourth quarter of 2026, resulting in Chemomab redomiciling to the U.S., listing on Nasdaq under ticker "SCIP," and becoming a wholly owned subsidiary of the combined company led by CEO Reginald Seeto. Chemomab Therapeutics Ltd. operates in the biotechnology industry, focusing on developing novel antibody-based therapies for cancer and inflammatory diseases.